Condition: Amyotrophic Lateral Sclerosis · Sponsor: Eli Lilly and Company
Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group: Sporadic Amyotrophic Lateral Sclerosis OL01 (NCT07571174). The studies aim to evaluate the safety and tolerability of different treatments in participants with Amyotrophic Lateral Sclerosis (ALS) that will last at least 96 weeks.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| UZ Leuven | Leuven, Belgium | Not Yet Recruiting |
| University Hospital - London Health Sciences Centre | London, Canada | Not Yet Recruiting |
| McGill University Health Centre | Montreal, Canada | Recruiting |
| Sunnybrook Research Institute | Toronto, Canada | Not Yet Recruiting |
| Universitätsklinikum Schleswig-Holstein | Lübeck, Germany | Not Yet Recruiting |
| Universitätsmedizin Rostock | Rostock, Germany | Not Yet Recruiting |
| Universitaetsklinikum Ulm | Ulm, Germany | Not Yet Recruiting |
| Universitair Medisch Centrum Utrecht | Utrecht, Netherlands | Not Yet Recruiting |
| Hospital Universitari de Bellvitge | L'Hospitalet de Llobregat, Spain | Not Yet Recruiting |
| Hospital Universitari i Politecnic La Fe | Valencia, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07571200